anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Amblyopia is the most common cause of monocular visual impairment in both children and young and middle-aged adults. Patching has been the mainstay of amblyopia therapy. It is generally held that the response to treatment is best when it is instituted at an early age, particularly by age two or three, and is poor when attempted after eight years of age.

For severe amblyopia, it is generally accepted that occlusion with patching is the standard of care. Other modalities of treatment, such as atropine penalization and optical penalization, are widely considered insufficient as initial treatments for severe amblyopia. However, controversy exists with regard to how many hours per day of patching should be prescribed. Advocates of full-time patching purport that such a regimen is needed to restore visual acuity more rapidly and more effectively. Advocates of part-time patching believe it to be better tolerated by the child and family, therefore producing less stress on the parent-child relationship and producing better results through better compliance. Part-time patching may also promote the development of binocularity in patients who have "straight-eyes", reduce the chance of a straight-eyed patient developing manifest strabismus or losing stereopsis, and reduce the incidence of reverse- or occlusion-amblyopia.

The study is a randomized trial comparing daily patching regimes for children with severe amblyopia. It will consist of about 160 children. Patients in the severe (20/100 to 20/400) group will patch part-time (6 hours) or full-time (all or all but one waking hour) of each day for the 4 month study period. There are at least two follow up visits during the 4-month period. Visual acuity is the major study outcome. It is assessed at the 4-month exam.
Pancreatin pellets are produced by a process employing extrusion techniques. In the process, a mixture of pancreatin powder and selected solvent is formed into a pliable mass suitable for extrusion. The extrusion is conducted followed by a cutting, shaping or forming of the extruded mass into pre-pellet like forms. Further drying and mechanical working of the pre-pellet forms results in the final pancreatin pellet of improved pharmaceutical and mechanical stability. A special aspect of the process is the selection of a solvent for mixing with pancreatin powder that is harmless to enzymes. Such solvents typically include isopropanol and acetone.
Perampanel oral tablet: 2mg by mouth every 24 hours for two weeks, then up-titrated by 2 mg every two weeks to a target dose of 6 mg/day. Minimum total daily dose = 2 mg/day. Maximum daily dose is 12 mg/day. Total daily dose will be determined by the Investigator based on tolerability and seizure control.
The utility model discloses a topical black plaster to treat hyperosteogeny. The plaster shows a layered structure. The mixture layer (2) of substrate and common Chinese medicine is pasted on the plaster cloth (1). A thin layer (3) of key and precious Chinese medicine is pasted on the mixture layer (2). The thin layer (3) is provided with a transdermal agent layer (4). The utility model is simple in structure. Because enough key and precious Chinese medicine composition and transdermal agent are clung to the skin, on the one hand, the waste of precious medicine can be avoided, on the other hand, the drug absorbing capacity of skin can be increased and satisfied efficacy can be reached.
BACKGROUND: Artificial intelligence is being used for rehabilitation, including monitoring exercise compliance through sensor technology. AI classification of shoulder exercise wearing an IMU sensor has only been reported in normal (i.e. painless) subjects. To prove the feasibility of monitoring exercise compliance, we aimed to classify 11 types of shoulder rehabilitation exercises using an AI (artificial intelligence) algorithm in patients with shoulder pain. We had the patients wear an IMU-based sensor, collected data during exercise, and determined the accuracy of exercise classification.
METHODS: Data were collected from 58 patients (27 males, 31 females, age range 37-82 years) diagnosed with shoulder diseases such as adhesive capsulitis and rotator cuff disease. 11 types of shoulder pain rehabilitation exercise programs were developed and repeated each exercise ten times per session while wearing an IMU sensor. The study applied the Rectified Linear Unit (ReLU) and the SoftMax as the activation function for hidden layers, the output layer.
RESULTS: The acquired data was used to train a DNN model using the multilayer perceptron algorithm. The trained model was used to classify 11 types of shoulder pain rehabilitation exercises. The training accuracy was 0.975 and the test accuracy was 0.925.
CONCLUSION: The study demonstrates that IMU sensor data can effectively classify shoulder pain rehabilitation exercises, providing more appropriate feedback for patients. The model can be utilized to establish a system for remotely monitoring patients' exercise performance. The use of deep learning in patient monitoring and rehabilitation has significant potential to bring innovative changes to healthcare service delivery.
Disclosed herein are systems and methods for immunity data creation and immunity monitoring (e.g., management, maintenance, etc.). A user may upload immunity and redaction data. A community of other users may verify the uploaded data. A venue may comprise a target immunity level and an actual immunity level. Combining the verified uploaded data with the actual immunity level may yield a new actual immunity level. The user may be allowed to enter the venue if the new actual immunity level is at or above the target immunity level.
The present invention is directed to a panel of monoclonal antibodies (Mabs) specific for murine prion protein PrP c . These Mabs can be applied to immunoblotting, cell surface immunofluorescent staining and immunohistochemistry at light and electron microscopy. Additionally, these Mabs recognize both the normal (PrP c ) and protease-resistant (PrP res ) isoforms of PrP. Some Mabs are species restricted, while others react with PrP from a broad range of mammals including mice, humans, monkeys, cows, sheep, squirrels and hamsters. Moreover, several of the Mabs selectively recognize different PrP glycoforms as well as the metabolic fragments of PrP c . These newly generated PrP c  antibodies are useful for exploring the biology of PrP c  and to establish the diagnosis of prion diseases in both humans and animals.
Telemedicine group will test blood glucose at least 4 times a day Each time the meter time-stamps the reading. All meter readings will upload to the cloud via "Myglucohealth" website, where they can be accessed by caregivers, including providers and parents. Parents will be notified by device about the blood glucose testing results. Provider will set device to alert patient or patient's family or send alerts if uploaded numbers are outside an identified range (\<70 mg/dL \> 300 mg/dL). As per the standard of care, parents are trained to administer sugar containing liquids, or inject extra insulin for hyperglycemia correction. Parents will be encouraged to contact study personnel if they are concerned about the diabetes control. Study personnel will access home blood glucose monitor data, and provide insulin dosing advice. Parents will be asked to upload blood glucose readings prior to each visit.
Aim 1 will determine how people with chronic stroke (PwCS) adapt their gait in response to different balance challenging environments. For Aim 1, the investigators will conduct a single-session cross sectional study to assess gait patterns during and immediately following walking practiced in balance challenging environments. PwCS will perform treadmill walking in a natural unmodified environment, and in two balance-challenging environments that will include a Movement Amplification Environment (MAE), and an unpredictable lateral perturbation environment. All enrolled participants will undergo clinical outcome measure assessments to identify baseline function. In addition, all participants in Aim 1 will undergo biomechanical testing while walking in each of the three environments to assess changes in their walking patterns.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to novel indolopyrrolocarbazole derivatives of sugars of the general formula (I)   where one of R 1  and R 1 a means hydrogen atom but other is not hydrogen atom; R 2  and   mean independently hydrogen atom, OH; R 3  and   mean independently hydrogen atom, OH; R 4  and   mean independently hydrogen atom, OH, azido-group, NH 2 , halogen atom;   mean independently H, OH, azido-group, NR 9 R 10 , halogen atom, C(O)Ra, SR, OSO 2 Rc, OR or in common they form =O under condition that R 2 ,R 3 ,R 4 ,R 5  and   and   all are not hydrogen atom simultaneously; R means hydrogen atom, C 1-7 -alkyl, heterocyclic 6-membered ring containing 1 or 2 nitrogen atoms as heteroatoms being indicated C 1-7 -alkyl can be substituted with phenyl; Ra means OH; Rc means C 1-7 -alkyl; R 6  means hydrogen atom, C 1-7 -alkyl, OH, NH 2  being indicated C 1-7 -alkyl can be substituted with phenyl which in turn can be substituted with C 1-7 -alkyl; R 7  and R 8  in common mean O; R 9  and R 10  mean independently hydrogen atom or in common with nitrogen atom to which they are bound form cyclic 6-membered nonaromatic ring containing one or two heteroatoms taken among the group N, O;   and   mean independently H, halogen atom, -C(O)Ra under condition that   and   are not 1,11-dichloro-group and under condition that when X 2  and   each means H, X 1  and   then each means independently H or halogen atom; R 1  means hexose; R 7  and R 8  in common mean O and each of R 2 ,R 5  and R 4  means OH;   and   each means H; Q means NH and in this case each of R 3  and R 6  is not NH 2  and R 3  is not methoxy-group when R 6  means H; W means C; Q means NH, O or S; or its pharmaceutically acceptable salt. Compounds of the formula (I) show activity with respect to topoisomerase-1 and can be used for inhibition of proliferation of tumor cells eliciting antitumor effect. Invention describes pharmaceutical composition and method of inhibition of tumor growth also. EFFECT: new compounds, valuable antitumor activity. 18 cl, 3 tbl, 106 ex
PURPOSE: To evaluate a deep learning-based pipeline using a Dense-UNet architecture for the assessment of acute intracranial hemorrhage (ICH) on non-contrast computed tomography (NCCT) head scans after traumatic brain injury (TBI).
MATERIALS AND METHODS: This retrospective study was conducted using a prototype algorithm that evaluated 502 NCCT head scans with ICH in context of TBI. Four board-certified radiologists evaluated in consensus the CT scans to establish the standard of reference for hemorrhage presence and type of ICH. Consequently, all CT scans were independently analyzed by the algorithm and a board-certified radiologist to assess the presence and type of ICH. Additionally, the time to diagnosis was measured for both methods.
RESULTS: A total of 405/502 patients presented ICH classified in the following types: intraparenchymal (n = 172); intraventricular (n = 26); subarachnoid (n = 163); subdural (n = 178); and epidural (n = 15). The algorithm showed high diagnostic accuracy (91.24%) for the assessment of ICH with a sensitivity of 90.37% and specificity of 94.85%. To distinguish the different ICH types, the algorithm had a sensitivity of 93.47% and a specificity of 99.79%, with an accuracy of 98.54%. To detect midline shift, the algorithm had a sensitivity of 100%. In terms of processing time, the algorithm was significantly faster compared to the radiologist's time to first diagnosis (15.37 ± 1.85 vs 277 ± 14 s, p < 0.001).
CONCLUSION: A novel deep learning algorithm can provide high diagnostic accuracy for the identification and classification of ICH from unenhanced CT scans, combined with short processing times. This has the potential to assist and improve radiologists' ICH assessment in NCCT scans, especially in emergency scenarios, when time efficiency is needed.
This protocol is a study of the use of Stereotactic Body Radiation Therapy (SBRT) for all types of primary or metastatic tumors near the spinal cord. The major goal of this study is to evaluate the efficacy and toxicity of a specific SBRT program in a prospective manner. The main outcome variables in this study are pain and neurologic function.

A major issue in delivering SBRT is the number of treatment sessions. There are advantages and disadvantages to both single and multi treatment programs. In this protocol, patients are offered SBRT with either a single treatment or 25 treatment days. This study is not designed to compare different SBRT schedules. A single treatment program is more convenient and likely to relieve symptoms sooner than a multi-session program. A program with 25 treatments may produce better long-term results. Our protocol uses life expectancy, patient preference, and tumor size to determine whether SBRT is delivered with 1 or 25 treatments.
Compositions of matter and methods of treating cancer patients are used to prevent or limit cardiotoxicity during or after cancer treatment with anthracycline drugs, and to prevent or lower resistance to anthracycline drugs, both of which are believed to be caused by the human enzyme carbonyl reductase. Thus, the compositions and methods may be used to reduce the dosages of anthracycline anti-cancer drugs necessary to produce a desired cancer-cell-killing performance. Preferred embodiments comprise treating cancer patients with a pharmaceutical composition comprising compounds having halogenated (or pseudo-halogenated) aryl groups, preferably halogenated (or pseudo-halogenated) arylcyanooximes or phenylcyanooximes and derivatives or analogs thereof, including those comprising —CL or —F, or other substituents on an aryl/phenyl ring. The preferred composition of arylcyanooxime(s) may be administered in a pharmaceutical composition also comprising at least one anthracycline compound, or may be administered separately from the at least one anthracycline compound. Especially-preferred arylcyanooximes include oximino(2,4-difluorophenyl)acetonitrile and/or oximino(2,6-difluorophenyl)acetonitrile and/or oximino(2,5-difluorophenyl)acetonitrile and/or oximino(2-chloro-6-fluorophenyl)acetonitrile and/or oximino(2,4-dichlorophenyl)acetonitrile and/or oximino(2,6-dichlorophenyl)acetonitrile. These six disubstituted halogenated arylcyanooximes may be synthesized using a nitrosation reaction of the respective phenylacetonitriles by neat organic nitrites at room temperature. Most preferably, a high yield of the substituted arylcyanoximes are obtained by nitrosating a substituted phenylacetonitrile by treatment with gaseous methylnitrite, CH 3 ONO, at room temperature or below.
BACKGROUND: Unstable atherosclerotic carotid plaques with intraplaque neovascularization (IPN) carry a substantial risk for ischemic stroke. Conventional ultrasound methods fall short in detecting IPN, where superb microvascular imaging (SMI) has emerged as a promising tool for both visualizing and quantification. High levels of fibroblast growth factor 23 (FGF-23) have, in observational studies, been suggested as related to cardiovascular morbidity and mortality. The association of FGF-23 to atherosclerotic carotid plaque instability remains relatively unexplored.
METHODS: A cohort of twenty-nine patients with ≥50% atherosclerotic carotid stenosis underwent conventional carotid ultrasound, SMI, and blood tests, including measurement of FGF-23 in plasma. Nineteen patients were characterized as symptomatic and ten as asymptomatic.
RESULTS: Our major findings were: i) Higher FGF-23 levels were strongly correlated with increased SMI-assessed IPN. ii) Neo-vessel count recorded by quantitative SMI was positively correlated to increased FGF-23 levels, but not with basic FGF levels. (iii) In contrast, traditional risk factors for plaque instability exhibited no noteworthy associations with SMI-assessed IPN or with FGF-23 levels.
CONCLUSION: This pilot study suggest the potential of FGF-23 as a valuable marker for neovascularization and atherosclerotic carotid plaque instability as a risk factor for ischemic stroke. Further research involving larger cohorts and prospective data is necessary to understand FGF-23's role in this context comprehensively.
A compact portable emergency aid apparatus (10) provides audible CPR instructions in any one' of a number of languages and site location of the emergency. A compact housing (11) has a plurality of inputs and has visual (13) and audio outputs (12) and has a battery power supply (23) located in the housing (11). A solid state memory chip (30), such as an EE prom, is used for digitally storing emergency instructions therein in multiple languages in a compressed format. A digital signal processor (26) or DSP is coupled to the solid state memory chip (30) for selecting and processing stored emergency instructions. The DSP (26) decompresses the stored instructions and converts the instructions into an analog signal for applying it to an audio circuit (32,33). The audio circuit (32,33) is connected to the audio output for receiving the retrieved audio instructions and producing them audibly through a speaker (34) or earphone (35). A GPS (27) receiver is coupled to a visual output for determining the location of an emergency. The compact nature of the apparatus allows it to be easily stored and used when an emergency situation arises.
Patients with FGFR1-3 mutation or translocation receive FGFR Inhibitor AZD4547 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Approval from Ethical Committee of Faculty of Medicine Universitas Indonesia was acquired prior conducting the study. Validation and reliability test were done for USG operators by assessing IVC in 20 patients supervised by intensivists. Subjects were given informed consent before participating in the study. Subjects underwent the chest x-ray examination with supine position. The measurement of VPW was done by radiologists, considered normal if the value is 53 ± 5 mm, overload if VPW \> 71 mm. The subjects then underwent the IVC diameter measurement using USG Philips En Visor C, with transthoracal subcostal approach. The result is considered normal if IVC diameter is 1.5 - 2.5 cm and overload if \>2.5 cm, otherwise the subjects is excluded. If the IVC can not be done, subjects will be excluded.
Psychotic manifestations are a classic feature of non-convulsive status epilepticus (NCSE) of temporal origin. For several decades now, the various psychiatric manifestations of NCSE have been described, and in particular, the diagnostic challenges they pose. However, studies using stereotactic-EEG (SEEG) recordings are very rare. Only a few cases have been reported, but they demonstrated the anatomical substrate of certain manifestations, including hallucinations, delusions, and emotional changes. The post-ictal origin of some of the manifestations should be emphasized. More generally, SEEG has shown that seizures affecting the temporal and frontal limbic systems can lead to intense emotional experiences and behavioural disturbances.
The comparison county SSP operates in the local health department and provides syringes, cookers/cottons, naloxone, wound care kits, condoms and lubricant, snacks, drinks, and sharps containers. A peer support specialist is present for consultation with clients upon request during SSP hours. The SSP will expand it hours from 3 hours/week to 40 hours/week at the same time the intervention county receives its KyOSK, to be comparable. SSP clients who enroll in the study will receive a swipe card linked to their SSP client identification. Card readers will be installed in the SSP for clients to swipe upon entry. Staff will provide clients with the same menu of supplies as those in the KyOSK and the same supply/time interval limits will be imposed. SSP clients will receive a resource guide.
PURPOSE: A serum-free medium for culturing animal cells is provided to lower production cost and to basically block contamination of animal materials. CONSTITUTION: A serum-free medium for culturing animal cells contains N-acetyl galactosamine of chemical formula 1. The N-acetyl galactosamine is isolated from Acanthopanax sessiliflorum seeman extract. Animal-derived serum is replaced with the N-acetyl galactosamine of chemical formula 1. The animal cells are animal-derived stem cells or skin cells. A cosmetic composition for improving skin condition contains a culture medium which is prepared by culturing animal cells in a serum-free meduium containing N-acetyl galactosamine of chemical formula 1.
African Americans have a higher prevalence of vascular disease than Caucasians. Vascular disease can lead to heart attacks, strokes and even amputations. Insulin, a hormone which is secreted by the pancreas, affects not only glucose and fat metabolism but also vascular disease. Impairment of insulin s ability to remove glucose from the circulation is known as insulin resistance. To overcome insulin resistance the pancreas secretes extra insulin. These high levels of insulin affect circulating triglyceride levels by both promoting production of triglyceride by the liver and interfering with clearance of triglyceride from the circulation. Triglyceride in turn contributes to the development of vascular disease by causing both inflammation and hypercoagulability.

Surprisingly African Americans are more insulin resistant and have a higher rate of vascular disease than Caucasians but have lower triglyceride levels. Because of the high rate of vascular diseases in African Americans, our aim is to determine if the adverse effects of triglyceride occur at a lower level in African Americans than Caucasians. To achieve this goal we will determine if there are differences in the effect of a meal on triglyceride levels and vascular function in a representative cohort of African American and Caucasian women.

For this study we will enroll 96 women (48 African American and 48 Caucasian women). We are recruiting women because ethnic differences in triglyceride are even greater in women than men. We are enrolling women between the ages of 18 and 65 years. The study will involve several outpatient visits to the NIH Clinical Center. The first visit will be a screening to determine eligibility. At the second visit a test to measure insulin resistance will be performed. This test is called a frequently sampled intravenous glucose tolerance test. The third visit will be for the test meal. Before and at 2, 4 and 6 hours after the meal, blood will be drawn and vascular function measured. Vascular function is determined by taking blood pressure and then measuring blood flow in the arm with ultrasound. It is possible that individual differences in diet could affect the results of the vascular study on the day of the test meal. Therefore for 7 days prior to the test meal, the NIH Clinical Center will provide to each participant all their meals in the form of either trays or meals in a box. These meals will be consistent with the typical American diet and be 33% fat, 15% protein and 52% carbohydrate. In designing these meals, the dietician will take into account individual food preferences.

This study is being performed in collaboration with the Harvard School of Public Health, the University of Texas Southwestern Medical Center and Indiana University. Therefore some blood drawn during Visits 2 and 3 will be sent coded, without personal identifiers, to each institution for analyses.
Subjects received 1 dose of Mencevax ACWY vaccine at Month 0. Mencevax ACWY vaccine was administered subcutaneously into the upper region of the non-dominant arm.